消化性潰瘍治療藥物的全球市場（2023-2030）：規模、佔有率、成長分析和類型預測（質子幫浦抑制劑（PPI）/組織胺 H2 受體拮抗）

消化性潰瘍治療市場規模預計將從2021年的44億美元和2022年的46億美元成長到2030年的64億美元，預測期內年複合成長率為3.5%。

由於多種因素，消化性潰瘍藥物市場正在穩步成長。消化性潰瘍病是一種常見的胃腸道疾病，罹患全球數百萬人，由於消化性潰瘍病患病率不斷增加、人口高齡化以及吸煙和飲酒等不健康習慣日益增加的生活習慣的推動，市場不斷成長。

醫療技術的進步和創新配方的發展也促進了市場的成長。然而，學名藥的可用性和替代治療方案的出現等因素給市場帶來了挑戰。儘管如此，由於人們越來越認知到消化性潰瘍病早期診斷和有效治療的重要性，預計市場將會成長。

消化性潰瘍藥物市場的主要趨勢之一是擴大採用質子幫浦抑制劑（PPI）作為首選。與其他藥物類別相比，質子幫浦抑制劑的卓越功效和安全性推動了這一趨勢。 PPI 可以長期緩解症狀，並透過抑制胃酸分泌來幫助潰瘍癒合。此外，配方的進步提高了 PPI 的生物利用度和患者的依從性。對 PPI 的日益偏好預計將推動對消化性潰瘍治療藥物的需求。

本報告調查了全球消化性潰瘍治療藥物市場，並提供了市場概況、市場各種影響因素分析、技術和創新趨勢、法律制度、市場規模趨勢和預測以及各個細分市場和地區。編制了單獨的細分、競爭形勢、主要企業簡介等。

目錄

• 執行摘要
• 調查方法
• 母市場分析
  • 市場概況
  • 市場規模
  • 市場動態
    • 促進因素
    • 機會
    • 抑制因素
    • 任務
• 關鍵市場洞察
  • 技術分析
  • 價格分析
  • 供應鏈分析
  • 價值鏈分析
  • 市場生態系統
  • 智慧財產權分析
  • 貿易分析
  • 啟動分析
  • 原料分析
  • 創新矩陣
  • 研發線產品分析
  • 總體經濟指標
  • 重點投資分析
  • 關鍵成功因素
  • 競爭程度
  • 市場動態及展望
    • 市場動態
      • 促進因素
      • 機會
      • 抑制因素
      • 任務
  • 法規狀況
  • 波特的分析
  • Skyquest 對未來顛覆的獨家見解
• 全球消化性潰瘍藥物市場：按類型
  • 市場概況
  • 質子幫浦抑制劑 (PPI)
  • 組織胺H2受體拮抗
  • 制酸劑
  • 抗生素
• 全球消化性潰瘍藥物市場按地區分類
  • 市場概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲
• 競爭形勢
  • 前5名企業對比
  • 主要企業市場地位
  • 主要企業的招募策略
  • 關鍵成功策略
  • 近期市集活動
  • 主要企業市場佔有率
• 主要企業簡介
  • MedicoPharm Ltd.
  • Pharmanova Inc.
  • Gastrotech Pharmaceuticals
  • BioCure Pharmaceuticals
  • Medix Corporation
  • PharmaPro Industries
  • Ulcerex Pharma
  • GastroMed Solutions
  • Digesta Pharmaceuticals
  • Healix Pharmaceuticals
  • Pepto Therapeutics
  • Gastronex Ltd.
  • DigestCare Pharmaceuticals
  • Ulcera Pharmaceuticals
  • GastroCure Inc.
  • Stomax Pharmaceuticals
  • Digestive Health Solutions
  • MedicoDigest
  • Gastropedia Pharmaceuticals
  • GastroGenix Corporation

Peptic Ulcer Drugs Market size was valued at USD 4.4 billion in 2021 and is poised to grow from USD 4.6 billion in 2022 to USD 6.4 billion by 2030, growing at a CAGR of 3.5% in the forecast period (2023-2030).

The global peptic ulcer drugs market is witnessing steady growth due to several factors. Peptic ulcer disease is a common gastrointestinal disorder that affects millions of people worldwide. The market for peptic ulcer drugs is driven by the increasing prevalence of peptic ulcer disease, the growing aging population, and the rising adoption of unhealthy lifestyle habits such as smoking and alcohol consumption.

Additionally, advancements in medical technology and the development of innovative drug formulations have contributed to the growth of the market. However, factors such as the availability of generic drugs and the emergence of alternative treatment options pose challenges to the market. Nonetheless, the increasing awareness about the importance of early diagnosis and effective treatment of peptic ulcers is expected to drive the market forward.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Peptic Ulcer Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Peptic Ulcer Drugs Market Segmental Analysis

The global peptic ulcer drugs market is segmented by type and region. Based on type, the market can be segmented into proton pump inhibitors (PPIs), histamine H2-receptor antagonists, antacids, and antibiotics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Peptic Ulcer Drugs Market Drivers

Increasing Prevalence Of Peptic Ulcers Worldwide

• One driver of the global peptic ulcer drugs market is the increasing prevalence of peptic ulcers worldwide. Peptic ulcers are a common gastrointestinal disorder affecting millions of people, and the demand for effective treatment options is growing. Factors such as unhealthy lifestyles, stress, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) contribute to the rising incidence of peptic ulcers. This drives the demand for peptic ulcer drugs, leading to market growth.

Peptic Ulcer Drugs Market Restraints

Availability Of Alternative Treatment Options

• One restraint of the global peptic ulcer drugs market is the availability of alternative treatment options. In addition to pharmaceutical drugs, there are non-pharmacological approaches such as lifestyle modifications, dietary changes, and natural remedies that are considered effective in managing peptic ulcers. Some individuals may prefer these alternatives, which can impact the demand for traditional peptic ulcer drugs. Moreover, the potential side effects and risks associated with long-term medication use may also lead to concerns among patients and healthcare providers, influencing the market dynamics.

Competitive Landscape for Global Peptic Ulcer Drugs Market

The global peptic ulcer drugs market is characterized by a mix of established companies and emerging players. Market participants are focusing on research and development activities to enhance the efficiency and performance of Peptic Ulcer Drugs. Additionally, strategic collaborations, partnerships, and mergers and acquisitions are prevalent strategies adopted by companies to expand their market presence. The competitive environment is further influenced by factors such as technological advancements, government regulations, and the ability to provide cost-effective and sustainable solutions.

Market Trends of Global Peptic Ulcer Drugs Key

• One key market trend in the global peptic ulcer drugs market is the increasing adoption of proton pump inhibitors (PPIs) as a preferred treatment option. PPIs are a class of drugs that reduce the production of stomach acid and provide effective relief from peptic ulcers. The trend is driven by the superior efficacy and safety profile of PPIs compared to other drug classes. PPIs offer long-lasting symptom relief and help in healing the ulcers by reducing acid production. Additionally, advancements in drug formulations have improved the bioavailability and patient compliance of PPIs. The growing preference for PPIs is expected to drive the demand for peptic ulcer drugs in the market.

Table of Contents

• Executive Summary
  • Market Overview
  • Wheel of Fortune
• Research Methodology
  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations
• Parent Market Analysis
  • Market Overview
  • Market Size
  • Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
• Key Market Insights
  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition
• Market Dynamics & Outlook
  • Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
  • Regulatory Landscape
  • Porters Analysis
• Competitive rivalry
• Threat of Substitute Products
• Bargaining Power of Buyers
• Threat of New Entrants
• Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
• Political Impact
• Economic Impact
• Social Impact
• Technical Impact
• Environmental Impact
• Legal Impact
• Global Peptic Ulcer Drugs Market by Type
  • Market Overview
  • Proton pump inhibitors (PPIs)
  • histamine H2-receptor antagonists
  • antacids
  • and antibiotics
• Global Peptic Ulcer Drugs Market Size by Region
  • Market Overview
  • North America
• USA
• Canada
  • Europe
• Germany
• Spain
• France
• UK
• Rest of Europe
  • Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
  • Latin America
• Brazil
• Rest of Latin America
  • Middle East & Africa (MEA)
• GCC Countries
• South Africa
• Rest of MEA
• Competitive Landscape
  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
• By Development
• By Company
• By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021
• Key Company Profiles
  • MedicoPharm Ltd. (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Pharmanova Inc. (Germany)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Gastrotech Pharmaceuticals (United Kingdom)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • BioCure Pharmaceuticals (Switzerland)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Medix Corporation (Japan)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • PharmaPro Industries (France)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Ulcerex Pharma (Canada)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • GastroMed Solutions (Australia)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Digesta Pharmaceuticals (Netherlands)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Healix Pharmaceuticals (India)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Pepto Therapeutics (Spain)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Gastronex Ltd. (Italy)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • DigestCare Pharmaceuticals (South Korea)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Ulcera Pharmaceuticals (Sweden)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • GastroCure Inc. (Brazil)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Stomax Pharmaceuticals (China)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Digestive Health Solutions (Mexico)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • MedicoDigest (Russia)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Gastropedia Pharmaceuticals (Argentina)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • GastroGenix Corporation (South Africa)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments